The Acute Myeloid Leukemia (AML) market was impacted by newly diagnosed, relapsed / refractory and mutation-based data presented during the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.

Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for VENCLEXTA® (venetoclax), DAURISMO® (glasdegib), TIBSOVO® (ivosidenib), XOSPATA® (gilteritinib), Iomab-B®, (targeted iodine (131I) apamistamab radioimmunotherapy), mivebresib, Hu5F9-G4, and AMG-553

Companies presenting data included: Abbvie, Actinium, Agios, Amgen, Astellas, Genentech, Pfizer.

Get immediate access to this 65-slide report so you can make better decisions today and prepare for tomorrow.

ACUTE MYELOID LEUKEMIA REPORT ASCO 2019

American Society of Clinical Oncology

Chicago, IL
May 31 to Jun 4

Share: